Pfizer denies Ranbaxy buyout talk

Pfizer said it isn't buying a majority stake in Ranbaxy Laboratories, quashing rumors that it might counter Daiichi Sankyo's bid for the Indian drugmaker. "I can tell you that we have no intention of buying the company," a spokesman told Dow Jones. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.